New drug LAD106 enters first human safety tests
NCT ID NCT07471932
First seen Mar 27, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage study is testing a new drug called LAD106 in 93 healthy adults aged 18 to 45. The main goal is to see if it is safe and how the body processes it. Participants will receive either LAD106, a similar drug (lebrikizumab), or a placebo. This research is a first step to gather basic safety information before testing in patients with a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Centre for Human Drug Research (CHDR) Phase 1 Unit
RECRUITINGLeiden, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAD106
What could go wrong
This is a very early Phase 1 study in healthy volunteers, so it cannot show whether LAD106 works for any disease. The main goal is safety, not effectiveness.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.